457.4000 -18.50 (-3.89%)
NSE Jan 12, 2026 15:31 PM
Volume: 1.3M
 

457.40
-3.89%
ICICI Securities Limited
Q2 results were lower than I-direct estimates on margin and profitability front. Revenues were in line with I-direct estimates. Despite pandemic and high base, the company has guided 15-20% growth based on strong order book position (albeit some expected delays). Regarding the optically high capex plan of | 600 crore for modernisation and technology upgradation, we believe this has to do with the need to cater to the changed priorities and requirements at the behest of the clients, the benefits of which may be visible in the long run. We continue to emphasise on the strong execution...
Promoters have decreased holdings from 66.41% to 57.49% in Sep 2025 qtr
More from Cohance Lifesciences Ltd.
Recommended